Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sorriso Pharmaceuticals

Request full access

A biotech firm developing disease-modifying antibodies for the treatment of inflammatory diseases

Sandy, United StatesFounded 2020Biotech & Life Sciences

About Sorriso Pharmaceuticals

Sorriso Pharmaceuticals is a clinical-stage biopharmaceutical company established in 2020, concentrating on the development of disease-modifying antibodies for immune-mediated inflammatory diseases. The company was founded by Ciara Kennedy, who serves as President and CEO. Dr. Kennedy has a track record of advancing therapeutic programs and previously led Amplyx Pharmaceuticals until its acquisition by Pfizer. The company officially launched in December 2021 with a significant $31 million Series A financing round co-led by New Enterprise Associates (NEA) and Arix Bioscience plc. This initial funding was aimed at progressing its pipeline of oral antibodies.

The company's core business revolves around its proprietary "Vorabody" platform, which engineers potent, single-domain antibodies for oral delivery. This technology is designed to create durable antibody fragments that remain stable and active within the gastrointestinal tract, allowing for localized treatment of inflammation. This approach targets the combined global market for inflammatory conditions, valued in excess of $50 billion. The business model focuses on developing these therapies through clinical trials to address unmet needs in patient populations that currently rely on systemic, injectable treatments. The oral delivery method aims to offer comparable efficacy to injections but with improved safety, reduced systemic exposure, and greater patient convenience.

Sorriso's pipeline includes several candidates, with the lead program being SOR102. This oral biologic is being developed for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. SOR102 functions as a bispecific antibody that simultaneously inhibits two validated drivers of IBD: TNF-alpha and IL-23. By combining these two mechanisms into a single oral therapy, SOR102 is designed to provide targeted action within inflamed intestinal tissue with minimal systemic absorption. The company initiated a first-in-human Phase 1/1b clinical trial for SOR102 in late 2023 to evaluate its safety and efficacy in patients with ulcerative colitis. In December 2024, Sorriso announced positive results from the Phase 1b trial, with plans to begin a Phase 2 trial in 2025. Other pipeline assets include SOR101 (an oral anti-TNFa) and SOR104 (an anti-IL-7Ra).

Source: Dealroom company data

At a glance

Status
Operational
Employees
14
Open positions
None listed
Dealroom signal
33.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Dec 2021 $31M $124M NEA · Arix Bioscience ↗
SPINOUT✓Other financing Jan 2020 $0 — Flanders Institute for Biotechnology · Vrije Universiteit Brussel —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Sorriso Pharmaceuticals website traffic

Latest recorded traffic for Sorriso Pharmaceuticals is 1.3K monthly website visits, down 38.1% over the last three months. Sorriso Pharmaceuticals's team declined 17.6% over the past year.

Latest monthly visits1.3K 3-month web change-38.1% 1-year team growth-17.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Sorriso Pharmaceuticals in the Sandy ecosystem

Live from Dealroom

The Sorriso Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • NEA
  • Arix Bioscience

Other known investors4 additional known investors

  • Flanders Institute for Biotechnology
  • Vrije Universiteit Brussel
  • Biovision Ventures
  • Pappas Capital
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States81.8%
🇨🇦 Canada9.1%
🇳🇱 Netherlands9.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sorriso Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sorriso Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.